Zinc-finger BED domain-containing 3 (Zbed3) is a novel secreted protein associated with insulin resistance in humans

Journal of Internal Medicine

Volumn 275, Issue 5, 2014, Pages 522-533

  Jia, Y ^a   Yuan, L ^a   Hu, W ^a   Luo, Y ^a   Suo, L ^a,b   Yang, M ^a   Chen, S ^a   Wang, Y ^a   Liu, H ^c   Yang, G ^a   Li, L ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Department of Special Consultation   (China)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Insulin resistance; Secreted protein; Zinc finger BED domain containing 3

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MESSENGER RNA; PROTEIN KINASE B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZINC FINGER BED DOMAIN CONTAINING 3 PROTEIN; ZINC FINGER PROTEIN;

ADIPOSE TISSUE; ADULT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

INSULIN RESISTANCE; SECRETED PROTEIN; ZINC-FINGER BED DOMAIN-CONTAINING 3;

ADIPOSE TISSUE; ANIMALS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MUSCLE, SKELETAL; OBESITY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84899072262     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12170     Document Type: Article

References (19)

1. O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 diabetes: the end of the beginning? Science 2005; 307: 370-3.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-46.
3. Sladek R, Rocheleau G, Rung J et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445: 881-5.
4. Zeggini E, Weedon MN, Lindgren CM et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336-41.
5. Lango H, Palmer CN, Morris AD et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 2008; 57: 3129-35.
6. Ohshige T, Iwata M, Omori S et al. Association of new loci identified in european genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS ONE 2011; 10: e26911-5.
7. Su AI, Cooke MP, Ching KA et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 2002; 99: 4465-70.
8. Zeng L, Fagotto F, Zhang T et al. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 1997; 90: 181-92.
9. Chen T, Li M, Ding Y et al. Identification of Zinc-finger BED Domain-containing 3 (Zbed3) as a Novel Axin- interacting Protein That Activates Wnt/β-Catenin Signaling. J Bio Chem 2009; 284: 6683-9.
10. Ouchi N, Higuchi A, Ohashi K et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010; 329: 454-7.
11. Farrah T, Deutsch EW, Omenn GS et al. A high-confidence human plasma proteome reference set with estimated concentrations in peptideatlas. Mol Cell Proteomics 2011; 10: M110006353. doi:10.1074/mcp M110.006353.
12. Xu B, Chen G, Shi P et al. shRNA-Mediated BAALC knockdown affects proliferation and apoptosis in human acute myeloid leukemia cells. Hematology 2012; 17: 35-40.
13. Ling L, Yang Y, Gangyi Y et al. The role of JAZF1 on lipid metabolism and related genes in vitro. Metabolism 2011; 60: 523-30.
14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
15. Wenjing H, Ling L, Mengliu Y et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endicrinol Metab 2013; 98: 290-8.
16. Ke L, Ling L, Mengliu Y et al. Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity. Eur J Endocrinol 2011; 164: 905-10.
17. Albareda M, Rodríguez-Espinosa J, Murugo M, de Leiva A, Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000; 43: 1507-11.
18. Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot- specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-61.
19. Jonsson A, Ladenvall C, Ahluwalia TS et al. Effect of common genetic variants associated with type 2 diabetes and glycemic traits on α- and β-cell function and insulin action in man. Diabetes 2013; 62: 2978-83.